GSK To Downplay Europe Because of Poor Innovation Support, Focuses On U.S. and Japan Instead
This article was originally published in The Pink Sheet Daily
GSK CEO Andrew Witty is scathing about the lack of support in Europe for innovation, and the company will now prioritize the U.S., Japan and emerging markets for the development of new products
You may also be interested in...
Bayer‘s Chairman Marijn Dekkers says the pharma sector’s poor public reputation and consequent loss of faith in the industry risks destroying the European drug business model.
The annual German prescription report suggests an additional €4.6 billion can be cut from the country’s annual drug expenditures, which could cause the government to extend its temporary price moratorium and mandatory rebate, as well as pursue other cost-cutting measures.
Emerging Markets, U.S. Provide Better Incubation Environment For Biotech Than Europe, Says Sanofi’s Viehbacher
Taking the helm of EFPIA, Viehbacher says R&D and innovation are the keys to rescuing Europe from its economic slump, but more harmonization across the pharmaceutical sector will be needed too.